



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865				
									APPLICANT(S): Benjamin OSHLACK et al.						
									FILING DATE: December 29, 2003		GROUP: 1614				
U.S. PATENT DOCUMENTS															
'EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
<i>JRL</i>	AA	2	7	7	0	5	6	9	11/56	Fromherz et al.	167	65			
<i>JRL</i>	AB	3	1	3	3	1	3	2	05/12/64	Loeb, et al.	264	49			
<i>JRL</i>	AC	3	1	7	3	8	7	6	03/16/65	Zobrist	252	137			
<i>JRL</i>	AD	3	2	7	6	5	8	6	10/04/66	Rosaen	210	90			
<i>JRL</i>	AE	3	3	3	2	9	5	0	7/67	Blumberg et al.	260	285			
<i>JRL</i>	AF	3	4	9	3	6	5	7	2/70	Lewenstein et al.	424	260			
<i>JRL</i>	AG	3	6	7	6	5	5	7	7/72	Lachman et al.	424	260			
<i>JRL</i>	AH	3	7	7	3	9	5	5	11/73	Pachter et al.	424	260			
<i>JRL</i>	AI	3	8	7	9	5	5	5	4/75	Pachter et al.	424	260			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
														YES	NO
<i>JRL</i>	AJ	8	3	0	3	1	9	7	9/83	WO	A61K	9/22			
<i>JRL</i>	AK	9	0	0	4	9	6	5	05/17/1990	WO	A61K	31/485			
<i>JRL</i>	AL	9	4	0	6	4	2	6	3/94	WO	A61K	31/46			
<i>JRL</i>	AM	9	5	0	3	8	0	4	2/95	WO	A61K	31/485			
<i>JRL</i>	AN	9	6	0	2	2	5	1	2/96	WO	A61K	31/485			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
<i>JRL</i>	AO	Foss, J.F., et al. Abstract, "Prevention of Apomorphine- or Cisplatin- induced emesis in the dog by combination of Methylnaltrexone and Morphine". Cancer Chemother Pharmacol (1998); 42(4):287-91.													
<i>JRL</i>	AP	Yuan et al., "Efficacy of Orally Administered Methylnaltrexone in Decreasing Subjective Effects After Intravenous Morphine", Drug and Alcohol Dependence (1998); 52:161-165.													
<i>JRL</i>	AQ	Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient-Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080.													
<i>JRL</i>	AR	Shen et al., "Ultra-Low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and Attenuate Tolerance/Dependence in Mice," Brain Research (1997), 757:176-190.													
<i>JRL</i>	AS	Yuan et al., "The Safety and Efficacy of Oral Methylnaltrexone in Preventing Morphine-induced Delay in Oral-Cecal Transit Time", Clinical Trials and Therapeutics (1997), 61:467-475.													
<i>JRL</i>	AT	Mendelson J., et al, "Buprenorphine and Naloxone Interactions in Opiate Dependent Volunteers," Clin. Phar. Ther. (1996), 60:105-114.													
<i>JRL</i>	AU	Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocain, Hydromorphone and their Combination in Humans," (1996) (Abstract only)													
EXAMINER		<i>Jeffrey E. Russell</i>							DATE CONSIDERED		<i>January 25, 2005</i>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.I134CON		SERIAL NO.: 10/747,865		
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)									APPLICANT(S): Benjamin OSHLACK et al.				
									FILING DATE: December 29, 2003		GROUP: 1614		
U.S. PATENT DOCUMENTS													
'EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JR</i>	BA	3	9	1	6	8	8	9	11/04/1975	Russell	128	145.8	
<i>JR</i>	BB	3	9	6	5	2	5	6	06/22/1976	Leslie	424	22	
<i>JR</i>	BC	3	9	6	6	9	4	0	6/76	Pachter et al.	424	260	
<i>JR</i>	BD	4	1	7	6	1	8	6	11/79	Goldberg	424	260	
<i>JR</i>	BE	4	2	3	7	1	4	0	12/02/1980	Dudzinski	424	260	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
<i>JR</i>	BF	9	7	3	3	5	6	6	9/97	WO	A61K	9/20	YES
<i>JR</i>	BG	9	8	3	5	6	7	9	8/98	WO	A61K	31/485	
<i>JR</i>	BH	9	9	3	2	1	2	0	7/99	WO	A61K	31/485	
<i>JR</i>	BI	0	0	0	1	3	7	7	01/13/2000	WO	A61K	31/00	
<i>JR</i>	BJ	8	7	0	1	2	8	2	03/12/1987	WO	A61K	31/485	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
<i>JR</i>	BK	Chih-Cheng Chien, et al., "Sigma Antagonists Potentiate Opioid Analgesia in Rats", Neuroscience Letters 190 (1995), 137-139.											
<i>JR</i>	BL	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995) 92:10540-10544.											
<i>JR</i>	BN	Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.											
<i>JR</i>	BO	Talwin NX, Physician's Desk Reference 48 <sup>th</sup> Ed. (1994) Montvale, NJ 2120-2121.											
<i>JR</i>	BP	Foss et al., "Dose related Antagonism of the Emetic Effect of Morphine by Methylnaltrexone in Dogs", J. Clin Pharmacol (1993), 33:747-751											
<i>JR</i>	BQ	Holmes et al., "Inhibiting Spinal Dynorphin A Component Enhances Intrathecal Morphine Antinociception in Mice", Anesth. Analg. (1993), 77:1166-73.											
<i>JR</i>	BR	Mizakowski et al., "Inhibition of Spinal Opioid Analgesia by Supraspinal Administration of Selective Opioid Antagonists", Brain Research (1992), 59:263-274.											
EXAMINER		<i>Jeffrey E. Russell</i>							DATE CONSIDERED		<i>January 25, 2005</i>		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)										APPLICANT(S): Benjamin OSHLACK et al.				
										FILING DATE: December 29, 2003		GROUP: 1614		
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>JRL</i>	CA	4	2	8	5	9	8	7	08/25/1981	Ayer, et al.	427	3		
<i>JRL</i>	CB	4	3	6	6	3	1	0	12/28/1982	Leslie	536	56		
<i>JRL</i>	CC	4	4	0	1	6	7	2	8/83	Portoghesi et al.	424	260		
<i>JRL</i>	CD	4	4	4	3	4	2	8	04/17/1984	Oshlack et al.	424	22		
<i>JRL</i>	CE	4	4	5	1	4	7	0	5/84	Ganti	424	260		
<i>JRL</i>	CF	4	4	5	7	9	3	3	7/84	Gordon et al.	424	260		
<i>JRL</i>	CG	4	4	6	4	3	7	8	8/84	Hussain et al.	424	260		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
<i>JRL</i>	CH	0	1	3	2	1	8	0	05/10/2001	WO (A2)	A61K	31/485		
<i>JRL</i>	CI	0	1	6	8	0	0	0	09/20/2001	WO (A2)	A61K	31/00		
<i>JRL</i>	CJ	0	1	3	7	7	8	5	05/31/2001	WO (A2)	A61K			
<i>JRL</i>	CK	0	1	5	2	8	5	1	07/26/2001	WO (A1)	A61K	31/485		
<i>JRL</i>	CL	0	1	8	5	2	5	7	11/15/2001	WO (A2)	A61P			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
<i>JRL</i>	CM	Weinhold et al., "Buprenorphine Alone and in Combination with Naltrexone in Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274.												
<i>JRL</i>	CN	Cappel et al., "Enhancement of Naloxone Induced Analgesia by Pretreatment with Morphine" Pharma. Bioch. & Behav. (1989), 34:425-427.												
<i>JRL</i>	CO	Vaccarino et al., "Analgesia Produced by Normal Doses of Opioid Antagonists Alone and in Combination with Morphine", Pain (1989), 36:103-109.												
<i>JRL</i>	CP	Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213.												
<i>JRL</i>	CQ	Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40.												
<i>JRL</i>	CR	Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. Clin. Pharmacol (1981), 21:162-168.												
<i>JRL</i>	CS	Translation of German patent application DE 43 25 465												
EXAMINER <i>Jeffrey E. Russell</i>									DATE CONSIDERED <i>January 25, 2005</i>					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)											APPLICANT(S): Benjamin OSHLACK et al.			
											FILING DATE: December 29, 2003			
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
YL	DA	4	5	7	3	9	9	5	3/86	Chen et al.	604	896		
YL	DB	4	5	8	2	8	3	5	4/86	Lewis et al.	514	282		
YL	DC	4	6	0	8	3	7	6	8/86	Pasternak	514	282		
YL	DD	4	6	6	1	4	9	2	4/87	Lewis et al.	514	282		
YL	DE	4	7	1	8	2	1	5	1/88	Goldberg	514	282		
YL	DF	4	7	3	0	0	4	8	3/88	Portoghesi et al.	546	45		
YL	DG	4	7	6	0	0	6	9	7/88	Rzeszotarski et al.	514	282		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
YL	DH	0	1	9	3	8	5	2	12/31/2001	WO (A2)	A61K	31/00		
YL	DI	0	9	1	3	1	5	2	6/99	EP	A61K	31/485		
YL	DJ	0	6	4	7	4	4	8	4/95	EP	A61K	31/485		
YL	DK	0	3	5	2	3	6	1	1/90	EP	A61K	31/485		
YL	DL	0	2	0	5	2	8	2	12/86	EP	A61K	9/22		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	DM	Alayrez-Fuentes, et al. "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System in Morphine Analgesia"; J. Pharm Pharmacol (2001), 53:1201-1205.												
	DN	Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52:659-663.												
	DO	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone", Naltrexone Research Monograph 20 (1980) p. 3-9												
	DP	Baum et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1967) Vol. 102, No. 4 p. 426-429.												
	DQ	Rapaka et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) p. 53-63.												
	DR	Bloom et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5 <sup>th</sup> National Conference on Methadone Treatment (1973) Vol 2, p. 1342-1349.												
EXAMINER		Jeffrey E. Rosel							DATE CONSIDERED		January 25, 2005			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
									APPLICANT(S): Benjamin OSHLACK et al.					
									FILING DATE: December 29, 2003		GROUP: 1614			
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>JER</i>	EA	4	7	6	9	3	7	2	9/88	Kreek et al.	514	282		
<i>JER</i>	EB	4	7	8	5	0	0	0	11/88	Kreek et al.	514	282		
<i>JER</i>	EC	4	8	0	3	2	0	8	2/89	Pastemak	514	282		
<i>JER</i>	ED	4	8	9	6	3	4	1	2/89	Chien et al.	424	448		
<i>JER</i>	EE	4	8	0	6	5	4	3	2/89	Choi	514	464		
<i>JER</i>	EF	4	8	0	6	5	5	8	2/89	Wuest et al.	514	381		
<i>JER</i>	EG	4	8	2	8	8	3	6	05/09/1989	Elger et al.	424	419		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
<i>JER</i>	EH	0	1	9	3	3	5	5	09/03/1986	EP (A3)	A61K	31/615		
<i>JER</i>	EI	0	3	1	9	2	4	3	06/07/1989	EP (A1)	A61K	31/485		
<i>JER</i>	EJ	0	3	1	9	2	4	3	11/07/1990	EP (B1)	A61K	31/485		
<i>JER</i>	EK	19	6	5	1	5	5	1	6/98	DE	A61K	31/485		
<i>JER</i>	EL	29	7	1	9	7	0	4	2/97	DE	A61K	31/485	x	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
EM	Bristoe et al., "Methoclopramox: Time Course of Changes in Altebrant-Reinforced Rhesus Monkeys"; Psychopharmacology (2000) 148:395-399.													
EN	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (3) (1983) p. 545-551.													
EO	Bullingham et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm (1983) 8: 332-343.													
EP	Calimlim, et al. "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and Therap (1974) Vol. 15; No. 6 pp.556-564.													
EQ	Caruso et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pp.1336-1341F.													
ER	Chemay, Nathan I., "Opioid Analgesics"; Drugs (1995) May 51 (5) pp. 713-737.													
ES	Chiang, et al. "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1995) 16, pp.1-8.													
EXAMINER	<i>Jeffrey E. Russell</i>							DATE CONSIDERED <i>January 25, 2005</i>						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865				
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)										APPLICANT(S): Benjamin OSHLACK et al.					
										FILING DATE: December 29, 2003		GROUP: 1614			
U.S. PATENT DOCUMENTS															
'EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
<i>JR</i>	FA	4	8	3	4	9	8	5	05/30/1989	Martani et al.	424	488			
<i>JR</i>	FB	4	8	3	4	9	8	4	05/30/1989	Goldie et al.	424	488			
<i>JR</i>	FC	4	8	3	4	9	8	5	05/30/1989	Elger et al.	424	488			
<i>JR</i>	FD	4	8	4	4	9	0	7	07/04/1989	Elger et al.	424	465			
<i>JR</i>	FF	4	8	4	4	9	0	9	07/04/1989	Goldie et al.	424	490			
<i>JR</i>	FF	4	8	4	4	9	1	9	07/04/1989	Leslie et al.	424	494			
<i>JR</i>	FG	4	8	6	1	9	0	9	8/89	Oshlak et al.	424	468			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
														YES	NO
<i>JR</i>	FH	4	3	2	5	4	6	5	2/95	DE	A61K	31/485		x	
<i>JR</i>	FI	2	2	2	2	6	3	9	11/72	DE	A61K	27/00			
<i>JR</i>	FJ	9	8	2	5	6	1	3	06/18/98	WO	A61K	31/485	abstract		
<i>JR</i>	FK	4	0	3	8	6	4	9	07/06/00	WO	A61K	9/00	abstract		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
PL	Chiang et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin Pharmacol Ther (1984) Vol 36 No. 5, pp.704-708.														
FM	Comer et al., "Depot Naltrexone: Long-lasting Antagonism of the Effects Of Heroin un Humans"; Psychopharmacology (2002) 159, pp.351-360														
EN	Crabtree et al., "Review of Naltrexone, a long-acting Opiate Antagonist"; Clinical Pharmacy, Vol. 3 (1984) pp.273-280.														
FO	Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability"; Dept. of Neuroscience, Albert Einstein College of Medicine Pain 82 (1999)pp.1-11.														
FP	Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability"; Dept. of Neuroscience, Albert Einstein College of Medicine Pain 84 (2000) pp.121-131.														
FQ	Fink et al., "naltrexone in Heroin Dependence"; Clin Pharm and Therap. Vol 9, No. 5,pp.568-577.														
FR	Fishman et al., "Disposition of Naloxone-7,8- <sup>3</sup> H in Normal & Narcotic Dependent Men"; J. Pharm. And Exper. Therap (1973)Vol 10 No. 2,pp.375-380.														
EXAMINER	<i>Jeffrey E. Russell</i>							DATE CONSIDERED <i>January 25, 2005</i>							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
		LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)							APPLICANT(S): Benjamin OSHLACK et al.				
									FILING DATE: December 29, 2003		GROUP: 1614		
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JR</i>	GA	4	8	6	1	7	6	1	8/89	Goldberg	514	282	
<i>JR</i>	GB	4	6	6	7	8	6	5	09/19/1989	Heafield et al.	424	461	
<i>JR</i>	GG	4	8	7	3	0	7	6	10/89	Fishman et al.	412	10	
<i>JR</i>	GD	4	8	8	2	3	3	5	11/89	Sinclair	514	282	
<i>JR</i>	GF	4	8	8	9	8	6	0	12/89	Rzeszotarski et al.	514	282	
<i>JR</i>	GF	4	9	3	5	4	2	8	6/90	Lewis	514	282	
<i>JR</i>	GG	4	9	4	0	5	8	7	07/10/1990	Jenkins et al.	424	480	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
<i>JR</i>	GH	00	4	5	9	4	7	7	8/16/01	WO	A61P		abstract
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	GI	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology I (1990) Vol 10, No. 2; pp.375-386.											
	GJ	Freye et al., "Effects of Tramadol and Tildine/Naloxone on Oral-Caecal Transit & Pupillary light Reflex"; Arzneim-Forsch/Drug Res. 50(4) (2000) pp. 24-30.											
	GK	Fudala, et al., "Effects of Buprenorphine and Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pp. 1-8.											
	GL	Fudala et al., "Human Pharmacology and Abuse Potential Of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pp. 360-366.											
	GM	Gal et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharm and Thera (1986) pp. 537-542.											
	GN	Genna et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pp. 35-41.											
	GO	Ghodse, et al., "Opioid analgesics and Narcotic Antagonists"; Side Effects of Drugs (2000) Annual 23, chpt 8 pp. 96-113.											
EXAMINER <i>Jeffrey E. Russell</i>									DATE CONSIDERED <i>January 25, 2005</i>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)										APPLICANT(S): Benjamin OSHLACK et al.			
										FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JR</i>	HA	4	2	0	0	0	9	8	04/29/1980	Ayer, et al.	128	260	
<i>JR</i>	HB	4	9	7	0	0	7	5	11/13/1990	Oshlak	424	451	
<i>JR</i>	HC	4	9	8	7	1	3	6	01/22/1991	Kreck et al.	514	282	
<i>JR</i>	HD	4	9	9	0	3	4	1	02/05/1991	Goldie et al.	424	484	
<i>JR</i>	HE	5	0	7	1	6	4	6	12/10/1991	Malkowska et al.	424	497	
<i>JR</i>	HF	5	0	7	5	3	4	1	12/91	Mendelson et al.	514	282	
<i>JR</i>	HG	5	0	8	0	6	5	6	2/92	Sinclair et al.	514	282	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
<i>JR</i>	HH	00	1	8	5	1	5	0	11/15/01	WO	A61K	31/00	YES      NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
<i>JR</i>	III	Chan, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol.17, No.3, pp. 193-197											
<i>JR</i>	FD	Gold, et al. "Rapid Opioid Detoxification During General Anesthesia"; Anesthesiology (1999) Vol 91, No 4, pp. 1639-1647.											
<i>JR</i>	HK	Greenwald, et al. "Comparative Clinical Pharmacology of Short Acting mu Opioids in Drug Abusers"; J. Pharm and Exper Therap (1996) Vol 277, No 3, pp. 1228-1236.											
<i>JR</i>	HL	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anesthesia (1974) Vol 29, pp. 33-39.											
<i>JR</i>	HM	Richter et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arzneim-Forsch/Drug Res. 35 (No II)(1985)pp. 1742-1744.											
<i>JR</i>	HN	Rosen et al., "The effect of Lamotrigine on Naloxone-precipitated Opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pp. 173-176.											
<i>JR</i>	HO	Rosen et al., "A Pilot Study of Dextromethorphan in Naloxone-Precipitated Opiate Withdrawal"; European J. of Pharm. (1996) Vol 307, pp. 251-257.											
EXAMINER							DATE CONSIDERED						
<i>Jeffrey E. Russell</i>							<i>January 25, 2005</i>						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO.: 200.1134CON	SERIAL NO.: 10/747,865		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)										APPLICANT(S): Benjamin OSHLACK et al.			
										FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>JR</i>	IA	5	0	9	1	1	0	9	02/25/1992	Heafield et al.	424	457	
<i>JR</i>	IB	5	0	9	6	7	1	5	3/92	Sinclair	424	449	
<i>JR</i>	IC	5	1	0	2	8	8	7	4/92	Goldberg	514	282	
<i>JR</i>	ID	4	1	6	0	0	2	9	07/03/1979	Ayer, et al.	424	15	
<i>JR</i>	IE	5	1	4	5	5	3	8	9/92	Granger et al.	424	449	
<i>JR</i>	IF	5	2	1	5	7	5	8	06/01/1993	Krishnamurthy	424	488	
<i>JR</i>	IG	5	2	2	5	4	4	0	7/93	London et al.	514	535	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
<i>JR</i>	IH	00	0	6	7	7	3	9	11/16/00	WO	A61K	31/00	YES      NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	IJ	Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846.											
	IK	Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174.											
	IL	Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pp. 210-211.											
	IM	Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458.											
	IN	Stine et al., "Use of Drug Combinations in Treatment of Opiod Withdrawal"; J. Clinical Psych (1992) Vol 12, No 3, pp. 203-209.											
	IO	Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242.											
	IP	Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993.											
	IQ	Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383.											
	IR	Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634.											
	IS	Tai, et al., "Naloxone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages											
EXAMINER	<i>Jeffrey E. Russell</i>								DATE CONSIDERED <i>January 25, 2005</i>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)												APPLICANT(S): Benjamin OSHLACK et al.			
												FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
JR		JA	5	2	2	6	3	3	1	07/13/1993	Thompson et al.	73	865.9		
JR		JB	5	2	3	6	7	1	4	8/93	Lee et al.	424	449		
JR		JC	5	2	5	6	6	6	9	10/93	Askanazi et al.	514	282		
JR		JD	5	2	6	6	3	3	1	11/30/1993	Oshlak et al.	424	468		
JR		JE	5	2	7	3	7	6	0	12/93	Oshlak et al.	424	486		
JR		JF	5	2	8	6	4	9	3	02/15/1994	Oshlak et al.	424	468		
JR		JG	5	3	1	6	7	5	9	12/93	Rose et al.	424	10		
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
JR		JH	00	0	5	1	5	9	2	9/05/00	WO	A61K	31/14	YES	NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
	II	Umbreit et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56 pp. 181-190													
	JK	Vaccarino et al., "Endogenous Opiates: 1999"; Peptides 21 (2000) pp. 1975-2034.													
	JL	Wang et al., "Inverse Agonists and neutral antagonists at $\mu$ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. Neurochemistry (2001) Vol 77, pp. 1590-1600.													
	JM	Wey et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pp. 252-261.													
	JN	Weinberg et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Thera (1988) Vol 44, No 3, pp. 335-342.													
	JO	Wells, et al., "In vivo Pharmacological Characterization of SNRI 9409, a Nonpeptidic Opioid $\mu$ -Agonist/ $\delta$ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper Thera (2001) Vol 297, No 2, pp. 597-605													
	JP	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pp. 4-6.													
	JO	Wright et al., "Acute physical dependence in Humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pp. 139-148.													
	JR	Zhu et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pp. 325-336.													
EXAMINER Jeffrey E. Russell								DATE CONSIDERED January 25, 2005							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)										APPLICANT(S): Benjamin OSHLACK et al.				
										FILING DATE: December 29, 2003		GROUP: 1614		
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>JM</i>	KA	5	3	1	7	0	2	2	5/94	Borsodi et al.	514	282		
<i>JM</i>	KB	5	3	2	1	0	1	2	6/94	Mayer et al.	514	25		
<i>JM</i>	KC	5	3	2	4	3	5	1	06/28/1994	Oshlak et al.	106	153		
<i>JM</i>	KD	5	3	3	6	6	9	1	08/09/1994	Raffa et al.	514	629		
<i>JM</i>	KE	5	3	5	2	6	8	0	10/94	Portoghesi et al.	514	279		
<i>JM</i>	KF	5	3	5	2	6	8	3	10/94	Mayer et al.	514	289		
<i>JM</i>	KG	5	3	5	6	4	6	7	10/18/1994	Oshlak et al.	106	153		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
<i>JM</i>	KH	0	1	5	8	4	5	1	08/19/2001	WO (A1)	A61K	31/485	YES	NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
<i>JM</i>	KI	<del>Han et al., "Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery; effect of formulation variable on drug release and mucoadhesive performance"; International J. Pharm (1999) Vol 177, pp. 201-209.</del>												
<i>JM</i>	KJ	<del>Handal et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12:7, pp. 438-445.</del>												
<i>JM</i>	KK	<del>Harris et al., "Buprenorphine and Naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pp. 85-94.</del>												
<i>JM</i>	KL	<del>Hawkes et al., "Effect of enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pp. 625-630.</del>												
<i>JM</i>	KM	<del>Hägger et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Thera (1999) Vol 37, No 8, pp. 377-385</del>												
<i>JM</i>	KN	<del>Budd, Keith, "Clinical Use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pp. 993-1011.</del>												
<i>JM</i>	KO	<del>Crain et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence"</del>												
<i>JM</i>	KP	<del>Howes et al., "The Pharmacology of TR5109, a new Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pp. 99-105.</del>												
<i>JM</i>	KQ	<del>Lelting et al., "Disposition and metabolism of codorphone in the rat, dog, and man"; Drug Metabolism and Disposition (1982) Vol 10, No 6, pp 649-653.</del>												
EXAMINER <i>Jeffrey E. Russell</i>										DATE CONSIDERED <i>January 25, 2005</i>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.II34CON		SERIAL NO.: 10/747,865			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)										APPLICANT(S): Benjamin OSHLACK et al.				
										FILING DATE: December 29, 2003		GROUP: 1614		
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>JR</i>	LA	5	3	5	6	9	6	0	10/94	Bihari et al.	514	282		
<i>JR</i>	LB	5	3	7	6	6	6	2	12/94	Ockert	514	282		
<i>JR</i>	LC	3	5	4	1	0	0	5	11/17/1970	Strathmann, et al.	210	19		
<i>JR</i>	LD	5	4	1	1	2	4	5	05/02/1995	Oshlack et al.	424	456		
<i>JR</i>	LE	5	4	2	6	1	1	2	06/95	Zagon et al.	514	282		
<i>JR</i>	LF	3	5	4	1	0	0	6	11/17/1970	Bixler, et al.	210	23		
<i>JR</i>	LG	5	4	5	7	2	0	8	10/95	Portoghesi et al.	546	35		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
<i>JR</i>	LH	0	8	8	6	3	5	2	02/03/1998	EP (B1)	A61K	31/485	YES	NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
LI	Amass et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) Vol 58, pp. 143-152.													
LJ	Hassain et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats"; (1987) Vol 36, pp. 127-130.													
LK	Jasinski et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. Pharm and Exper Thera (1967) Vol 157, No 2, pp. 420-426.													
LM	Jones et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusinh humans"; Drug and Alcohol Dependence (2000) Vol 60, pp.29-37.													
LN	Kanof et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J Pharma and Exper Thera (19920 Vol 260, No. 1, pp. 355-363.													
LO	King et al., "Naltrexone-Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study"; Alcoholism: Clin and Exper Res (1997) Vol 21, No 5, pp. 906-909.													
LP	Kogan et al., "Estimation of the Systemic Availability and Other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Commu. In Chem. Path. And Pharm (1977) Vol 18, No. 1, pp 29-34.													
LQ	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin-Addicts"; Amer J of Psychiatry (1994) Vol 1, p 151.													
LR	Kosten et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, OO. 73-78.													
LS	Kurland et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No 5, pp. 663-672.													
EXAMINER	<i>Jeffrey E. Russell</i>							DATE CONSIDERED <i>January 25, 2005</i>						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)								APPLICANT(S): Benjamin OSHLACK et al.					
								FILING DATE: December 29, 2003		GROUP: 1614			
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>JRL</i>	MA	5	4	6	0	8	2	6	10/24/1995	Merrill et al.	424	470	
<i>JRL</i>	MB	5	4	7	2	7	1	2	12/05/1995	Oshlack et al.	424	480	
<i>JRL</i>	MC	5	4	7	2	9	4	3	12/95	Crain et al.	514	12	
<i>JRL</i>	MD	5	4	7	8	5	7	7	12/26/1995	Sackler et al.	424	489	
<i>JRL</i>	ME	5	4	8	6	3	6	2	1/96	Kitchell et al.	424	426	
<i>JRL</i>	MF	5	5	0	0	2	2	7	03/19/1996	Oshlack et al.	424	476	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	MG												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	MH	Lee et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pp.810-815											
	MI	Lehman, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory effects of Buprenorphine"; Eur. J. Clin Pharm (1988) Vol 34, pp. 343-352.											
<i>JRL</i>	MJ	Levine et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest (1988) Vol 82, pp. 1574-1577.											
	MK	Loimer et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pp. 157-160.											
	ML	Martin et al. "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim-Forsch /Drug Res. (1999) Vol 49, pp. 599-607.											
	MM	Martin et al., "Demonstration of Tolerance to and Physical Dependence on N-allynormorphine (Nalorphine)"; J. Of Pharm and Exper Thera (1965) Vol 150, No 3. Pp. 437-442.											
	MN	Mendelson et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pp. 37-46.											
	MO	Mendelson et al., "Buprenorphine and naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pp. 1095-1101.											
	MP	Nutt et al., "Methadone-naloxone mixture for use in methadone maintenance programs"; Clin Pharm and Ther. Vol 15, No 2, pp 156-166											
EXAMINER	<i>Jeffrey E. Russell</i>							DATE CONSIDERED <i>January 25, 2005</i>					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON	SERIAL NO.: 10/747,865					
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)									APPLICANT(S): Benjamin OSHLACK et al.						
									FILING DATE: December 29, 2003	GROUP: 1614					
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
<i>JR</i>	NA	5	5	0	2	0	5	8	3/96	Mayer et al.	514	289			
<i>JR</i>	NB	5	5	C	8	0	4	7	04/16/1996	Oshlack et al.	424	468			
<i>JR</i>	NC	5	5	0	8	0	4	3	04/16/1996	Krishnamurthy	424	484			
<i>JR</i>	ND	5	5	1	2	5	7	8	4/96	Crain et al.	514	282			
<i>JR</i>	NE	5	5	1	4	0	8	0	5/96	Weber et al.	514	249			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
														YES	NO
	NF														
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
NG	<del>Parwatikar et al., "Methadone-naloxone in combination for the Treatment of Heroin Addicts"; Clin. Pharm and Ther., Vol 14, No. 6, pp 941-948.</del>														
NH	<del>Parwatikar et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pp. 1350-1354.</del>														
NI	<del>Pitts et al., "Antinociceptive and Response Rate-Altering Effects of Kappa Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in Combination with Opioid Antagonists in Squirrel Monkeys"; J of Pharm and Exper Thera (1994) Vol 271, No 3; pp. 1501-1508.</del>														
NJ	<del>Preston et al., "Buprenorphine and Naloxone alone and in combination in Opioid-dependant Humans"; Psychopharmacology (1988), Vol 94, pp. 484-490.</del>														
NK	<del>Preston et al., "Differential Naloxone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J of Pharm and Ezper Thera (1993) Vol 264, No 2 pp. 813-823.</del>														
NL	<del>Preston et al., "Effects of Sublingually given naloxone in Opioid-dependant human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pp. 27-34.</del>														
NM	<del>Bigelow et al., "Abuse Liability and Assessment of Buprenorphine-Naloxone Combinations"; Dept of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, pp. 145-149.</del>														
NN	<del>Wikler et al., "N-Allylnormorphine: Effects of single dose and Precipitation of Acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post addicts)"; N-Allylnormorphine During Narcotic Addiction (1953) pp. 8-20.</del>														
EXAMINER	<i>Jeffrey E. Russel</i>								DATE CONSIDERED			<i>January 25, 2005</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)										APPLICANT(S): Benjamin OSHLACK et al.				
										FILING DATE: December 29, 2003		GROUP: 1614		
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>JER</i>	OA	5	5	3	4	4	9	2	7/96	Aston et al.	514	608		
<i>JER</i>	OB	5	5	4	9	9	1	2	08/27/1996	Oshlack et al.	424	468		
<i>JER</i>	OC	5	5	5	2	4	2	2	09/03/1996	Gauthier et al.	514	368		
<i>JER</i>	OD	5	5	5	6	8	3	8	9/96	Mayer et al.	514	25		
<i>JER</i>	OE	5	5	7	4	0	5	2	11/96	Rose et al.	514	343		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	OF													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
OO	Zaks et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No 13, pp. 2108-2110.													
OH-	Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No 1, pp. 54-58.													
OI	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pp. 209-213.													
OJ	Bashaw et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J of Clin Pharm and Thea (1995) Vol 33, No 9, 524-529.													
OK	Jasinski, D.R., "Assessment of the Abuse Potentality of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pp. 197-258.													
OL	Johnson et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pp. 519-526.													
OM	Strain et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No 2, pp. 206-217.													
ON	Preston et al., "Abuse liability and studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) vol 28, pp. 49-82.													
OO	Brennscheidt et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tiliidine/Naloxone Solution or Tiliidine/Naloxone Sustained Release Tablets"; Arzeim-Forsch/Drug Res. (2000) Vol 50, pp. 1015-1022.													
EXAMINER	<i>Jeffrey E. Russell</i>									DATE CONSIDERED <i>January 25, 2005</i>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)										APPLICANT(S): Benjamin OSHLACK et al.				
										FILING DATE: December 29, 2003		GROUP: 1614		
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
JR	PA	5	5	7	8	7	2	5	11/96	Portoghesi et al.	546	35		
JR	PB	5	5	8	0	8	7	6	12/96	Crain et al.	514	282		
JR	PC	5	5	8	5	3	4	8	12/96	Crain et al.	514	12		
JR	PD	5	5	9	1	4	5	2	01/04/1997	Miller et al.	424	468		
JR	PE	5	6	0	7	8	4	5	02/11/1997	Buxton et al.	424	495		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	PF													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
JR	PG	Bensley, "Function of Myocardial $\alpha$ -Adrenoceptors"; Life Sciences (1982) vol 31, pp. 101-112.												
JR	PH	Levine et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J of Clin Invest. (1988) Vol 82, pp. 1547-1577.												
JR	PI	Yoburn et al., "Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration"; Brain Research Bulletin (1994), Vol 33, pp. 237-240.												
JR	PI	Bunzow et al., "Molecular Cloning and Tissue Distribution of a Putative Member of the Rat Opioid Receptor Gene Family that is not a $\mu$ , $\delta$ , or $\kappa$ opioid receptor type"; FEBS letters (1994) pp. 284-288.												
JR	PK	Mollereau et al., "ORL 1, a novel member of the opioid receptor family: Cloning, functional expression and localization"; FEBS letters 341 (1994), pp. 33-38.												
JR	PL	Wang, et al., "cDNA cloning of an orphan opiate receptor gene family member and its splice variant"; FEBS letters 348 (1994) pp. 75-79.												
JR	PM	Suzuki et al., "Morphine conditioned place preference after chronic treatment with naloxone in the rat"; Research Communications in Substance Abuse (1991) vol 12., No 3., pp. 119-131.												
EXAMINER Jeffrey E. Russel								DATE CONSIDERED January 25, 2005						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865				
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)										APPLICANT(S): Benjamin OSHLACK et al.					
										FILING DATE: December 29, 2003		GROUP: 1614			
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
<i>JR</i>	QA	5	6	1	6	4	0	1	4/97	Khanna et al.	514	399			
<i>JR</i>	QB	5	6	2	2	2	2	2	04/22/1997	Knott et al.	424	494			
<i>JR</i>	QC	5	6	2	4	9	3	2	4/97	Qin et al.	514	282			
<i>JR</i>	QD	5	6	3	3	2	5	9	5/97	Qin et al.	514	282			
<i>JR</i>	QE	5	6	3	9	4	7	6	06/17/1997	Oshlack et al.	424	468			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
														YES	NO
	QF														
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
<i>JR</i>	QG	Press Release "International Patent Application to Be Published on Abuse-Resistant Pain Reliever Being Developed by Perdue Pharma"; August 8, 2001.													
<i>JR</i>	QH	Paronis et al., "Increased Analgesic Potency of Mu Agonists after Continuous Naloxone Infusion in Rats"; J fo Pharm Exper Thera (1991), 259 (2), pp. 582-589.													
<i>JR</i>	QI	Yoburn et al., "Supersensitivity to Opioid Analgesics Following Chronic Opioid Antagonist Treatment: Relationship to Receptor Sensitivity"; Pharmacology Bio Bch (1995) Vol 51 No. 2, pp. 535-539.													
<i>JR</i>	QJ	Crain et al., "Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia"; Brain Research (2001) Vol 888, pp. 75-82.													
<i>JR</i>	QK	Zhang et al., "Down-Regulation of $\mu$ -Opioid Receptors in Rat and Monkey Dorsal Root Ganglion Neurons and Spinal Cord After Peripheral Axotomy"; Neuroscience (1998) Vol 82., pp. 223-240.													
<i>JR</i>	QI	Abdulla et al., "Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons"; J of Neuro Sci (1998) Vol 18, pp 9685-9694.													
<i>JR</i>	QM	Di Giannuario et al., "Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats"; Neurosci. Lett (1999) Vol 272 pp. 183-186.													
EXAMINER <i>Jeffrey E. Russel</i>									DATE CONSIDERED <i>January 25, 2005</i>						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)										APPLICANT(S): Benjamin OSHLACK et al.				
										FILING DATE: December 29, 2003		GROUP: 1614		
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>JRN</i>	RA	5	6	5	6	2	9	5	08/12/1997	Oshlack et al.	424	468		
<i>JRN</i>	RB	5	6	7	0	1	7	2	09/23/1997	Buxton et al.	424	495		
<i>JRN</i>	RC	5	6	7	2	3	6	0	09/30/1997	Sackler et al.	424	490		
<i>JRN</i>	RD	5	6	8	1	5	8	5	10/28/1997	Oshlack et al.	424	490		
<i>JRN</i>	RE	5	7	6	3	4	5	2	06/09/1998	Miller et al.	514	282		
<i>JRN</i>	RF	5	7	6	7	1	2	5	06/98	Crain et al.	514	282		
<i>JRN</i>	RG	5	7	8	6	4	7	9	07/14/1998	Kim	514	282		
<i>JRN</i>	RH	5	7	6	7	1	2	5	06/16/1988	Crain, et al.	514	282		
<i>JRN</i>	RI	6	0	9	6	7	5	6	08/01/2000	Crain, et al.	514	282		
<i>JRN</i>	RJ	6	1	9	4	3	4	2	02/27/01	Crain, et al.	514	2		
<i>JRN</i>	RK	6	3	6	2	1	9	4	03/26/2002	Crain, et al.	514	285		
<i>JRN</i>	RL	6	3	9	5	7	0	5	05/28/2002	Crain, et al.	514	2		
<i>JRN</i>	RM	20	01	00	06	9	6	2	07/05/2001	Crain, et al.	514	253.04		
<i>JRN</i>	RN	20	01	00	18	4	1	3	08/30/2001	Crain, et al.	514	2		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	RO													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
<i>JRN</i>	RP	Ciccocioppo et al., "Effect of Nociceptin/orphanin FQ on the Rewarding Properties of Morphine"; Eur. J Pharmacol (2000) Vol 404, pp. 153-159.												
	RO	Physician's Desk Reference (2001) see Revia pp. 1146-1149 and Oxycontin, pp. 2697-2701												
	RR													
	RS													
EXAMINER	<i>Jeffrey E. Russell</i>							DATE CONSIDERED <i>January 25, 2005</i>						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)								APPLICANT(S): Benjamin OSHLACK et al.					
								FILING DATE: December 29, 2003		GROUP: 1614			
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>JRN</i>	SA	5	8	1	1	1	2	6	09/22/1998	Krishnamurthy	424	498	
<i>JRN</i>	SB	5	8	3	4	4	7	7	11/10/1998	Mioduszewski	514	282	
<i>JRN</i>	SC	5	8	4	3	4	8	0	12/01/1998	Miller et al.	424	484	
<i>JRN</i>	SD	5	8	4	9	2	4	0	12/15/1998	Miller et al.	264	460	
<i>JRN</i>	SE	5	8	5	8	0	1	7	1/99	Demopoulos et al.	604	890.1	
<i>JRN</i>	SF	5	8	6	0	9	5	0	1/99	Demopoulos et al.	604	49	
<i>JRN</i>	SG	5	8	6	6	1	6	4	2/99	Kuczynski et al.	424	472	
<i>JRN</i>	SH	5	4	0	9	9	4	4	04/25/1995	Black et al.	514	359	
<i>JRN</i>	SI	5	1	3	0	3	1	1	07/14/1992	Guillaumet et al.	514	234.2	
<i>JRN</i>	SJ	4	4	0	1	6	7	2	08/30/1983	Portoghesi	424	260	
<i>JRN</i>	SK	4	4	5	7	9	3	3	07/03/1984	Gordon et al.	424	260	
<i>JRN</i>	SL	5	4	3	6	2	6	5	07/25/1995	Black et al.	514	420	
<i>JRN</i>	SM	5	6	3	9	7	8	0	06/17/1997	Lau et al.	514	419	
<i>JRN</i>	SN	5	6	0	4	2	6	0	02/18/1997	Guay et al.	514	605	
<i>JRN</i>	SO	5	6	0	4	2	5	3	02/18/1997	Lau et al.	514	415	
<i>JRN</i>	SP	5	5	9	3	9	9	4	01/14/1997	Batt et al.	514	252	
<i>JRN</i>	SQ	5	5	3	6	7	5	2	07/16/1996	Ducharme et al.	514	602	
<i>JRN</i>	SR	5	5	5	0	1	4	2	08/27/1996	Ducharme et al.	514	365	
<i>JRN</i>	SS	5	5	2	1	2	1	3	05/28/1996	Prasit et al.	514	443	
<i>JRN</i>	ST	5	5	1	0	3	6	8	04/23/1996	Lau et al.	514	419	
<i>JRN</i>	SU	5	4	7	4	9	9	5	12/12/1995	Ducharme et al.	514	241	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	SX												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	SY												
EXAMINER	<i>Jeffrey E. Russell</i>						DATE CONSIDERED <i>January 25, 2005</i>						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)										APPLICANT(S): Benjamin OSHLACK et al.				
										FILING DATE: December 29, 2003		GROUP: 1614		
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>JR</i>	TA	5	8	6	0	0	9	7	02/09/1999	Wong et al.	424	473		
<i>JR</i>	TB	5	8	7	9	7	0	5	03/09/1999	Heafield et al.	424	464		
<i>JR</i>	TC	5	8	8	0	1	3	2	3/99	Hill	514	282		
<i>JR</i>	TD	5	8	9	1	4	7	1	04/06/1999	Miller et al.	424	468		
<i>JR</i>	TE	5	9	0	8	8	4	8	06/01/1999	Miller et al.	514	282		
<i>JR</i>	TF	5	9	4	2	2	4	1	8/99	Chasin et al.	424	426		
<i>JR</i>	TG	5	9	5	8	4	5	2	09/28/1999	Oshlack et al.	424	457		
<i>JR</i>	TH	3	8	4	5	7	7	0	11/05/1974	Theeuwes et al.	128	260		
<i>JR</i>	TI	4	0	6	3	0	6	4	12/13/1977	Saunders et al.	219	121		
<i>JR</i>	TJ	4	0	8	8	8	6	4	05/09/1978	Theeuwes et al.	219	121		
<i>JR</i>	TK	4	2	9	3	5	3	9	10/06/1981	Ludwig et al.	429	19		
<i>JR</i>	TL	4	9	5	7	6	8	1	09/18/1990	Klimesch et al.	264	211.23		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	TM													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
TN														
TO														
TP														
TQ														
TR														
TS														
EXAMINER	<i>Jeffrey E. Russel</i>							DATE CONSIDERED <i>January 25, 2005</i>						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)												APPLICANT(S): Benjamin OSHLACK et al.			
												FILING DATE: December 29, 2003		GROUP: 1614	
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
<i>JER</i>	UA	5	9	5	6	4	5	9	09/28/1999	Chasin et al.	424	490			
<i>JER</i>	UB	5	9	6	5	1	6	1	10/12/1999	Oshlack et al.	424	457			
<i>JER</i>	UC	5	9	6	5	1	6	3	10/12/1999	Miller et al.	424	468			
<i>JER</i>	UD	5	9	6	8	5	4	7	10/99	Reder et al.	424	449			
<i>JER</i>	UE	5	9	6	8	5	5	1	10/19/1999	Oshlack et al.	424	490			
<i>JER</i>	UF	5	9	7	2	9	5	4	10/99	Foss	514	282			
<i>JER</i>	UG	5	9	9	8	4	3	4	12/99	Mitch et al.	514	210.16			
<i>JER</i>	UH	3	1	7	3	9	7	7	03/16/1965	Jackson et al.	252	138			
<i>JER</i>	UI	4	5	8	7	1	1	8	05/06/1986	Hsiao	424	459			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
		UJ	04	0	5	2	3	4	6	06/24/2004	WO(A1)	A61K	9/62	YES	NO
		UK	9	5	4	8	4	4	8	09/06/2000	EP (B1)	A61K	9/50	abstract	
		UL	9	9	1	3	7	9	9	03/25/1999	WO (A1)	A61F	2/02		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
	UM														
	UN														
	UO														
	UP														
	UQ														
	UR														
	US														
EXAMINER										DATE CONSIDERED					
<i>Jeffrey E. Russell</i>										<i>January 25, 2005</i>					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.:	SERIAL NO.:				
									200.1134CON	10/747,865				
		LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)							APPLICANT(S): Benjamin OSHLACK et al.					
									FILING DATE: December 29, 2003	GROUP: 1614				
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>JBL</i>	VA	6	0	2	4	9	8	2	02/15/2000	Oshlack et al.	424	476		
<i>JBL</i>	VB	6	0	6	8	8	5	5	05/30/2000	Leslie et al.	424	468		
<i>JMN</i>	VC	6	0	7	7	5	3	2	06/20/2000	Malkowska et al.	424	457		
<i>JBL</i>	VD	6	0	7	7	5	3	3	06/20/2000	Oshlack et al.	424	461		
<i>JBL</i>	VE	6	1	0	3	2	5	8	08/15/2000	Simon	424	449		
<i>JBL</i>	VF	6	1	0	3	2	6	1	08/15/2000	Chasin et al.	424	459		
<i>JBL</i>	VG	6	1	4	3	3	2	2	11/07/2000	Sackler et al	424	459		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES
	VH													NO
	VI													
	VJ													
	VK													
	VL													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	VM													
	VN													
	VO													
	VP													
	VQ													
	VR													
	VS													
EXAMINER	<i>Jeffrey B. Russell</i>								DATE CONSIDERED	<i>January 25, 2005</i>				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO.:	SERIAL NO.:			
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)								200.1134CON	10/747,865					
								APPLICANT(S): Benjamin OSHLACK et al.						
								FILING DATE: December 29, 2003	GROUP: 1614					
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>JR</i>	WA	6	1	4	3	3	2	8	11/07/2000	Heafield et al.	424	489		
<i>JR</i>	WB	6	1	6	2	4	6	7	12/19/2000	Miller et al.	424	468		
<i>JR</i>	WC	6	2	1	0	7	1	4	04/03/2001	Oshlack et al.	424	476		
<i>JR</i>	WD	6	2	2	8	8	6	3	05/08/2001	Palermo et al.	514	282		
<i>JR</i>	WE	6	2	5	4	8	9	7	07/03/2001	Miller et al.	424	468		
<i>JR</i>	WF	6	2	6	1	5	9	9	07/17/2001	Oshlack et al.	424	457		
<i>JR</i>	WG	6	2	7	7	3	8	4	08/21/2001	Kaiko et al.	424	400		
FOREIGN P/TENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WH													
	WI													
	WJ													
	WK													
	WL													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	WM													
	WN													
	WO													
	WP													
	WQ													
	WR													
	WS													
EXAMINER	<i>Jeffrey E. Russell</i>							DATE CONSIDERED <i>January 25, 2005</i>						

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623			
		LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)							APPLICANT(S): Benjamin OSHLACK et al.					
									FILING DATE: December 29, 2003		GROUP: 1614			
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	XA	6	2	9	4	1	9	5	09/25/2001	Oshlack et al.	424	457		
	XB	6	3	0	6	4	3	6	10/23/2001	Oshlack et al.	424	468		
	XC	6	3	2	6	0	2	7	12/04/2001	Miller et al.	424	457		
	XD	6	3	3	5	0	3	3	01/01/2002	Oshlack et al.	424	457		
	XE	6	3	7	5	9	5	7	04/23/2002	Kaiko et al.	424	400		
	XF	6	3	8	7	4	0	4	05/14/2002	Oshlack et al.	424	480		
	XG	6	3	9	9	0	9	6	06/04/2002	Miller et al.	424	464		
	XH	6	4	7	5	4	9	4	11/05/2002	Kaiko et al.	424	400		
	XI	6	6	2	7	6	3	5	09/30/2003	Palermo, et al.	514	282		
	XJ	6	7	1	6	4	4	9	04/06/2004	Oshlack, et al.	424	449		
	XK	6	6	0	6	0	8	9	02/24/2004	Oshlack et al.	424	465		
	XL	6	6	0	6	0	6	6	02/24/2004	Kaiko et al.	424	400		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	XM													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	XN													
	XO													
	XP													
	XQ													
	XR													
	XS													
	XT													
EXAMINER		DATE CONSIDERED												
<i>Jeffrey E. Russell</i>		<i>January 25, 2005</i>												

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.